Search details
1.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci
; 115(4): 1296-1305, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38402853
2.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-38575731
3.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32469185
4.
Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping.
Value Health
; 26(4): 487-497, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36503033
5.
Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.
Value Health
; 26(8): 1155-1163, 2023 08.
Article
in English
| MEDLINE | ID: mdl-36805576
6.
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib.
Future Oncol
; 19(3): 217-228, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36749292
7.
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.
Future Oncol
; 19(10): 683-696, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36999526
8.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Br J Cancer
; 126(6): 889-898, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34963703
9.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Jpn J Clin Oncol
; 51(8): 1261-1268, 2021 Aug 01.
Article
in English
| MEDLINE | ID: mdl-34037224
10.
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
Proc Natl Acad Sci U S A
; 115(26): E6030-E6038, 2018 06 26.
Article
in English
| MEDLINE | ID: mdl-29875142
11.
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
Target Oncol
; 19(2): 191-201, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38492157
12.
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
J Thorac Oncol
; 19(3): 409-424, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37838086
13.
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
J Thorac Oncol
; 19(5): 829-838, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38154515
14.
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Cancer
; 119(2): 356-62, 2013 Jan 15.
Article
in English
| MEDLINE | ID: mdl-22810899
15.
Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
Cancer Med
; 12(24): 21605-21614, 2023 12.
Article
in English
| MEDLINE | ID: mdl-38062905
16.
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
J Thorac Oncol
; 18(4): 516-526, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36240971
17.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clin Cancer Res
; 29(8): 1423-1428, 2023 04 14.
Article
in English
| MEDLINE | ID: mdl-36729110
18.
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Cell Rep Med
; 4(11): 101280, 2023 11 21.
Article
in English
| MEDLINE | ID: mdl-37944528
19.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37270698
20.
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.
Int J Radiat Oncol Biol Phys
; 116(5): 1091-1099, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-36889516